Sakhaee K - Search Results

1

Increased propensity for calcium phosphate kidney stones with topiramate use.

Vega D, Maalouf NM, Sakhaee K. Vega D, et al. Among authors: sakhaee k. Expert Opin Drug Saf. 2007 Sep;6(5):547-57. doi: 10.1517/14740338.6.5.547. Expert Opin Drug Saf. 2007. PMID: 17877442 Review.

2

Citrate therapy for calcium phosphate stones.

Rimer JD, Sakhaee K, Maalouf NM. Rimer JD, et al. Among authors: sakhaee k. Curr Opin Nephrol Hypertens. 2019 Mar;28(2):130-139. doi: 10.1097/MNH.0000000000000474. Curr Opin Nephrol Hypertens. 2019. PMID: 30531474 Review.

3

Control of metabolic predisposition to cardiovascular complications of chronic kidney disease by effervescent calcium magnesium citrate: a feasibility study.

Quiñones H, Hamdi T, Sakhaee K, Pasch A, Moe OW, Pak CYC. Quiñones H, et al. Among authors: sakhaee k. J Nephrol. 2019 Feb;32(1):93-100. doi: 10.1007/s40620-018-0559-2. Epub 2018 Nov 21. J Nephrol. 2019. PMID: 30465137 Free PMC article. Clinical Trial.

4

Relationship between Urinary Calcium and Bone Mineral Density in Patients with Calcium Nephrolithiasis.

Sakhaee K, Maalouf NM, Poindexter J, Adams-Huet B, Moe OW. Sakhaee K, et al. J Urol. 2017 Jun;197(6):1472-1477. doi: 10.1016/j.juro.2017.01.002. Epub 2017 Jan 5. J Urol. 2017. PMID: 28063842 Free PMC article.

5

Temporal Changes in Kidney Stone Composition and in Risk Factors Predisposing to Stone Formation.

Xu LHR, Adams-Huet B, Poindexter JR, Maalouf NM, Moe OW, Sakhaee K. Xu LHR, et al. Among authors: sakhaee k. J Urol. 2017 Jun;197(6):1465-1471. doi: 10.1016/j.juro.2017.01.057. Epub 2017 Jan 20. J Urol. 2017. PMID: 28111301 Free PMC article.

6

Animal protein and the risk of kidney stones: a comparative metabolic study of animal protein sources.

Tracy CR, Best S, Bagrodia A, Poindexter JR, Adams-Huet B, Sakhaee K, Maalouf N, Pak CY, Pearle MS. Tracy CR, et al. Among authors: sakhaee k. J Urol. 2014 Jul;192(1):137-41. doi: 10.1016/j.juro.2014.01.093. Epub 2014 Feb 8. J Urol. 2014. PMID: 24518789 Clinical Trial.

7

Prevalence and spot urine risk factors for renal stones in children taking topiramate.

Corbin Bush N, Twombley K, Ahn J, Oliveira C, Arnold S, Maalouf NM, Sakhaee K. Corbin Bush N, et al. Among authors: sakhaee k. J Pediatr Urol. 2013 Dec;9(6 Pt A):884-9. doi: 10.1016/j.jpurol.2012.12.005. Epub 2013 Feb 1. J Pediatr Urol. 2013. PMID: 23375465 Free PMC article.

8

Post-renal transplantation hypophosphatemia.

Sakhaee K. Sakhaee K. Pediatr Nephrol. 2010 Feb;25(2):213-20. doi: 10.1007/s00467-009-1252-4. Epub 2009 Jul 15. Pediatr Nephrol. 2010. PMID: 19603188 Free PMC article. Review.

9

Metabolic basis for low urine pH in type 2 diabetes.

Maalouf NM, Cameron MA, Moe OW, Sakhaee K. Maalouf NM, et al. Among authors: sakhaee k. Clin J Am Soc Nephrol. 2010 Jul;5(7):1277-81. doi: 10.2215/CJN.08331109. Epub 2010 Apr 22. Clin J Am Soc Nephrol. 2010. PMID: 20413437 Free PMC article. Clinical Trial.

10

Increased production and reduced urinary buffering of acid in uric acid stone formers is ameliorated by pioglitazone.

Maalouf NM, Poindexter JR, Adams-Huet B, Moe OW, Sakhaee K. Maalouf NM, et al. Among authors: sakhaee k. Kidney Int. 2019 May;95(5):1262-1268. doi: 10.1016/j.kint.2018.11.024. Epub 2019 Feb 19. Kidney Int. 2019. PMID: 30795852 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results